Brosman S A, Lamm D L
Department of Surgery/Urology, UCLA Medical Center.
J Urol. 1990 Aug;144(2 Pt 1):313-5. doi: 10.1016/s0022-5347(17)39441-7.
The increasing use of bacillus Calmette-Guerin in the treatment of patients with low stage bladder cancer will inevitably bring attention to problems of proper use and toxicity. There is a need to identify patients who are most likely to benefit from this therapy and those who may be at risk for serious complications.
卡介苗在低分期膀胱癌患者治疗中的应用日益增多，这必然会引发对其合理使用及毒性问题的关注。有必要确定最有可能从该治疗中获益的患者，以及那些可能有发生严重并发症风险的患者。
